Abstract
Objective:
To investigate secretory phospholipase A2 (sPLA2) activity in neonatal sepsis.
Study Design:
Plasma sPLA2 activity, C-reactive protein (CRP) concentration, leukocyte count and immature/total neutrophil (I/T) ratio were assessed in a group of 156 infants admitted for neonatal intensive care, who were classified as documented sepsis (n=24), suspected infection (n=77) and controls (n=55). Interleukin-6 (IL-6) concentrations were assessed in a subgroup (n=29).
Result:
sPLA2 activity, CRP concentration and I/T ratio were higher in sepsis than in suspected infection or control groups. sPLA2 activity advanced with increasing CRP, I/T ratio and IL-6 was highest in infants with respiratory distress syndrome (RDS). Compared to CRP, sPLA2 had equal sensitivity and lower specificity. Compared to I/T ratio, sensitivity and specificity of sPLA2 were higher.
Conclusion:
Plasma sPLA2 activity is increased in neonatal sepsis and highest in infants with RDS. Further studies should assess the potential of sPLA2 inhibition in neonatal sepsis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Klein JO . Bacterial sepsis and meningitis. In: Remington JS, Klein JO (eds). Infectious Diseases of the Fetus and Newborn Infant. Saunders: Philadelphia, 2000, pp 943–998.
Schultz C, Rott C, Temming P, Schlenke P, Moller JC, Bucsky P . Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res 2002; 51: 317–322.
Lewis DBWC . Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In: Remington JS, Klein JO (eds). Infectious Diseases of the Fetus and Newborn Infant. Saunders: Philadelphia, 2000, pp 23–138.
Anderson MR, Blumer JL . Advances in the therapy for sepsis in children. Pediatr Clin North Am 1997; 44: 179–205.
Arndt P, Abraham E . Immunological therapy of sepsis: experimental therapies. Intensive Care Med 2001; 27 (Suppl 1): S104–S115.
Vadas P, Scott K, Smith G, Rajkovic I, Stefanski E, Schouten BD et al. Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock. Life Sci 1992; 50: 807–811.
Endo S, Inada K, Nakae H, Takakuwa T, Yamada Y, Suzuki T et al. Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis. Res Commun Mol Pathol Pharmacol 1995; 90: 413–421.
Nevalainen TJ, Eerola LI, Rintala E, Laine VJ, Lambeau G, Gelb MH . Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim Biophys Acta 2005; 1733: 210–223.
Yedgar S, Cohen Y, Shoseyov D . Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 2006; 1761: 1373–1382.
Touqui L, Arbibe L . A role for phospholipase A2 in ARDS pathogenesis. Mol Med Today 1999; 5: 244–249.
Beers SA, Buckland AG, Koduri RS, Cho W, Gelb MH, Wilton DC . The antibacterial properties of secreted phospholipases A2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall. J Biol Chem 2002; 277: 1788–1793.
Rintala EM, Aittoniemi J, Laine S, Nevalainen TJ, Nikoskelainen J . Early identification of bacteremia by biochemical markers of systemic inflammation. Scand J Clin Lab Invest 2001; 61: 523–530.
Dollner H, Vatten L, Linnebo I, Zanussi GF, Laerdal A, Austgulen R . Inflammatory mediators in umbilical plasma from neonates who develop early-onset sepsis. Biol Neonate 2001; 80: 41–47.
Schrama AJ, de Beaufort AJ, Sukul YR, Jansen SM, Poorthuis BJ, Berger HM . Phospholipase A2 is present in meconium and inhibits the activity of pulmonary surfactant: an in vitro study. Acta Paediatr 2001; 90: 412–416.
Byrjalsen I, Ingwersen SH . Immunoturbidimetry of serum C-reactive protein in low concentration of polyethylene glycol. Ann Clin Biochem 1985; 22: 269–272.
Mehr S, Doyle LW . Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J 2000; 19: 879–887.
Crowl RM, Stoller TJ, Conroy RR, Stoner CR . Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem 1991; 266: 2647–2651.
Gambero A, Landucci EC, Toyama MH, Marangoni S, Giglio JR, Nader HB et al. Human neutrophil migration in vitro induced by secretory phospholipases A2: a role for cell surface glycosaminoglycans. Biochem Pharmacol 2002; 63: 65–72.
Pruzanski W, Saito S, Stefanski E, Vadas P . Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes. Inflammation 1991; 15: 127–135.
Lambeau G, Lazdunski M . Receptors for a growing family of secreted phospholipases A2 . Trends Pharmacol Sci 1999; 20: 162–170.
Takasaki J, Kawauchi Y, Urasaki T, Tanaka H, Usuda S, Masuho Y . Antibodies against type II phospholipase A2 prevent renal injury due to ischemia and reperfusion in rats. FEBS Lett 1998; 440: 377–381.
Furue S, Mikawa K, Nishina K, Shiga M, Ueno M, Tomita Y et al. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med 2001; 29: 719–727.
Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den BH . A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997; 18: 111–115.
Mittendorf R, Covert R, Montag AG, elMasri W, Muraskas J, Lee KS et al. Special relationships between fetal inflammatory response syndrome and bronchopulmonary dysplasia in neonates. J Perinat Med 2005; 33: 428–434.
Berger C, Uehlinger J, Ghelfi D, Blau N, Fanconi S . Comparison of C-reactive protein and white blood cell count with differential in neonates at risk for septicaemia. Eur J Pediatr 1995; 154: 138–144.
Verboon-Maciolek MA, Thijsen SF, Hemels MA, Menses M, van Loon AM, Krediet TG et al. Inflammatory mediators for the diagnosis and treatment of sepsis in early infancy. Pediatr Res 2006; 59: 457–461.
Rintala E, Pulkki K, Mertsola J, Nevalainen T, Nikoskelainen J . Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand J Infect Dis 1995; 27: 39–43.
Marshall LA, Hall RH, Winkler JD, Badger A, Bolognese B, Roshak A et al. SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J Pharmacol Exp Ther 1995; 274: 1254–1262.
Song SM, Lu SM, Wang ZG, Liu JC, Guo SQ, Li Z . Subcellular membrane impairment and application of phospholipase A2 inhibitors in endotoxic shock. Injury 1999; 30: 9–14.
Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E . LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005; 33: 1741–1748.
Acknowledgements
We thank the technical assistants and nurses of the neonatal unit for collection of blood samples, Wim van Dam, laboratory technician, Department of Clinical Chemistry, for performing CRP measurements, A Bakker, laboratory technician Division of Neonatology, for performing IL-6 measurements and Professor/Dr K Zwinderman, Department of Medical Statistics for his advice. This project was sponsored by a Dutch NWO grant (no. 920-03-083).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schrama, A., de Beaufort, A., Poorthuis, B. et al. Secretory phospholipase A2 in newborn infants with sepsis. J Perinatol 28, 291–296 (2008). https://doi.org/10.1038/sj.jp.7211929
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211929